GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (NAS:SCNI) » Definitions » 3-Year FCF Growth Rate

Scinai Immunotherapeutics (Scinai Immunotherapeutics) 3-Year FCF Growth Rate : 47.60% (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Scinai Immunotherapeutics 3-Year FCF Growth Rate?

Scinai Immunotherapeutics's Free Cash Flow per Share for the three months ended in Sep. 2023 was $-0.48.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 47.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 22.80% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -6.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 12 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Scinai Immunotherapeutics was 47.60% per year. The lowest was -58.90% per year. And the median was -18.60% per year.


Competitive Comparison of Scinai Immunotherapeutics's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Scinai Immunotherapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinai Immunotherapeutics's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Scinai Immunotherapeutics's 3-Year FCF Growth Rate falls into.



Scinai Immunotherapeutics 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Scinai Immunotherapeutics  (NAS:SCNI) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Scinai Immunotherapeutics 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinai Immunotherapeutics (Scinai Immunotherapeutics) Business Description

Traded in Other Exchanges
Address
Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR
BiondVax Pharmaceuticals Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline.
Executives
Samuel J Moed director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Mark Germain director, other: Chairman WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Uri Ben-or officer: Chief Financial Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Yael Margolin director 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Adi Raviv director STRAUS CAPITAL GROUP, 411 HACKENSACK AVENUE, 7TH FLOOR, HACKENSACK NJ 07601
Morris C Laster director 11 REUVEN SHARI ST., JERUSALEM L3 9724611
Tamar Ben-yedidia officer: Chief Scientist 6 HAZIT ST., MAZKERET BATIA L3 7685421
Avner Rotman director 21 EISENBERG ST., REHOVOT L3 7628905
Amir Reichman director, officer: Chief Executive Officer 269 NAHAL FARAN ST., TAL SHAHAR L3 7680500
Elad Mark officer: Chief Operating Officer 27 HAILANOT, HERZLIYA L3 4631214
George Lowell director 33 DERECH BEIT LECHEM ST., JERUSALEM L3 9355317
Jay Green director 354 CONCESSION 10 E, FREELTON, ON Z4 L8B 1H6